drugset / Trial / NCT04558684
Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
Phase 1/2
Suspended
30 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
This is a open-label, single-arm study to investigate the safety and efficacy of Total neoadjuvant chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy in patients with rectal cancer.
Timeline
- Start
- 2019-11-01
- Primary completion
- 2020-09-30
- Completion
- 2023-12-30
Outcome
Outcome not reported
Stopped (Enrollment): “Inadequate patient enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Capecitabine | Small molecule | 2000 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |